What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.”In the company’s words, NCT05646524 on ClinicalTrials.gov
- Tested for
- Paroxysmal Nocturnal Hemoglobinuria (2 trials), PNH - Paroxysmal Nocturnal Hemoglobinuria, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Dermatomyositis, aHUS - Atypical Hemolytic Uremic Syndrome, IgA Nephropathy, C3 Glomerulopathy
- Main trialPhase 2
- “This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).”In the company’s words, NCT05646524 on ClinicalTrials.gov
- Given with
- Soliris (Alexion Pharm)Other companies’ drugs in its trials
Other drugs for Paroxysmal Nocturnal Hemoglobinuria
Coming up8
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- Jul 2029Phase 2 trial completes · ClinicalTrials.gov
- Aug 2029Phase 1/2 trial completes · ClinicalTrials.gov
- Apr 2030Phase 2 trial completes · ClinicalTrials.gov
- Dec 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Aug 2027 | Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy | |
| Phase 2Not yet recruiting | Sep 2027 | Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 2Not yet recruiting | Oct 2027 | Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) | |
| Phase 2Not yet recruiting | Nov 2027 | Study of NM8074 in Patients with Dermatomyositis (DM) | |
| Phase 2Not yet recruiting | Jul 2029 | Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris | |
| Phase 2Not yet recruiting | Apr 2030 | Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy | |
| Phase 2Not yet recruiting | Dec 2030 | Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) | |
| Phase 1/2Not yet recruiting | Aug 2029 | Study of NM8074 in Adult C3 Glomerulopathy Patients | |
| Phase 1Completed | 15 Jun 2022 | First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026